Emcure Pharmaceuticals Achieves Robust Q4FY25 Performance with 19% Revenue Growth and 63% Profit After Tax Growth administrator admin Date 22 May, 2025 Share: Prev Emcure Joins the 2025 Ice Bucket Challenge Revival, but with a Twist around Mother’s Day Emcure Pharmaceuticals to Acquire Remaining Stake in its Subsidiary, Zuventus Healthcare Ltd. Next
